Testing effectiveness (Phase 2)Looking for participantsNCT06100237
What this trial is testing
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
Who this might be right for
Multiple Myeloma
Carl Ola Landgren, MD, PhD 50